211 related articles for article (PubMed ID: 17317844)
21. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.
Tazzari PL; Tabellini G; Bortul R; Papa V; Evangelisti C; Grafone T; Martinelli G; McCubrey JA; Martelli AM
Leukemia; 2007 May; 21(5):886-96. PubMed ID: 17361225
[TBL] [Abstract][Full Text] [Related]
22. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: in vitro and in vivo study.
Martins AS; Ordoñez JL; García-Sánchez A; Herrero D; Sevillano V; Osuna D; Mackintosh C; Caballero G; Otero AP; Poremba C; Madoz-Gúrpide J; de Alava E
Cancer Res; 2008 Aug; 68(15):6260-70. PubMed ID: 18676850
[TBL] [Abstract][Full Text] [Related]
23. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.
Attias-Geva Z; Bentov I; Fishman A; Werner H; Bruchim I
Gynecol Oncol; 2011 May; 121(2):383-9. PubMed ID: 21295335
[TBL] [Abstract][Full Text] [Related]
24. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma.
Garg V; Zhang W; Gidwani P; Kim M; Kolb EA
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5446-54. PubMed ID: 17875774
[TBL] [Abstract][Full Text] [Related]
25. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells.
Gariboldi MB; Ravizza R; Monti E
Biochem Pharmacol; 2010 Aug; 80(4):455-62. PubMed ID: 20488164
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
Mukohara T; Shimada H; Ogasawara N; Wanikawa R; Shimomura M; Nakatsura T; Ishii G; Park JO; Jänne PA; Saijo N; Minami H
Cancer Lett; 2009 Sep; 282(1):14-24. PubMed ID: 19345478
[TBL] [Abstract][Full Text] [Related]
27. Doxorubicin modulates telomerase activity in Ewing's sarcoma in vitro and in vivo.
Lanvers-Kaminsky C; Winter B; Koling S; Frodermann B; Braun Y; Schaefer KL; Diallo R; Koenemann S; Wai D; Willich N; Poremba C; Schuck A
Oncol Rep; 2005 Sep; 14(3):751-8. PubMed ID: 16077987
[TBL] [Abstract][Full Text] [Related]
28. In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type.
Benini S; Perbal B; Zambelli D; Colombo MP; Manara MC; Serra M; Parenza M; Martinez V; Picci P; Scotlandi K
Oncogene; 2005 Jun; 24(27):4349-61. PubMed ID: 15824736
[TBL] [Abstract][Full Text] [Related]
29. Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
Höpfner M; Huether A; Sutter AP; Baradari V; Schuppan D; Scherübl H
Biochem Pharmacol; 2006 May; 71(10):1435-48. PubMed ID: 16530734
[TBL] [Abstract][Full Text] [Related]
30. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
Baumann P; Hagemeier H; Mandl-Weber S; Franke D; Schmidmaier R
Anticancer Drugs; 2009 Apr; 20(4):259-66. PubMed ID: 19240643
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
[TBL] [Abstract][Full Text] [Related]
33. VEGF(165), but not VEGF(189), stimulates vasculogenesis and bone marrow cell migration into Ewing's sarcoma tumors in vivo.
Zhou Z; Reddy K; Guan H; Kleinerman ES
Mol Cancer Res; 2007 Nov; 5(11):1125-32. PubMed ID: 18025258
[TBL] [Abstract][Full Text] [Related]
34. In vitro antiproliferative effects of albumin-doxorubicin conjugates against Ewing's sarcoma and peripheral neuroectodermal tumor cells.
Gabor F; Wollmann K; Theyer G; Haberl I; Hamilton G
Anticancer Res; 1994; 14(5A):1943-50. PubMed ID: 7847832
[TBL] [Abstract][Full Text] [Related]
35. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
Piao W; Wang Y; Adachi Y; Yamamoto H; Li R; Imsumran A; Li H; Maehata T; Ii M; Arimura Y; Lee CT; Shinomura Y; Carbone DP; Imai K
Mol Cancer Ther; 2008 Jun; 7(6):1483-93. PubMed ID: 18566219
[TBL] [Abstract][Full Text] [Related]
36. Antitumor activity of GSK1904529A, a small-molecule inhibitor of the insulin-like growth factor-I receptor tyrosine kinase.
Sabbatini P; Rowand JL; Groy A; Korenchuk S; Liu Q; Atkins C; Dumble M; Yang J; Anderson K; Wilson BJ; Emmitte KA; Rabindran SK; Kumar R
Clin Cancer Res; 2009 May; 15(9):3058-67. PubMed ID: 19383820
[TBL] [Abstract][Full Text] [Related]
37. [shRNA-mediated insulin-like growth factor I receptor gene silencing inhibits cell proliferation, induces cell apoptosis, and suppresses tumor growth in non-small cell lung cancer: in vitro and in vivo experiments].
Dong AQ; Kong MJ; Ma ZY; Qian JF; Fan JQ; Xu XH
Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(21):1506-9. PubMed ID: 17785094
[TBL] [Abstract][Full Text] [Related]
38. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
39. Differential mechanisms of acquired resistance to insulin-like growth factor-i receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model.
Huang F; Hurlburt W; Greer A; Reeves KA; Hillerman S; Chang H; Fargnoli J; Graf Finckenstein F; Gottardis MM; Carboni JM
Cancer Res; 2010 Sep; 70(18):7221-31. PubMed ID: 20807811
[TBL] [Abstract][Full Text] [Related]
40. Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.
Garofalo C; Mancarella C; Grilli A; Manara MC; Astolfi A; Marino MT; Conte A; Sigismund S; Carè A; Belfiore A; Picci P; Scotlandi K
Mol Endocrinol; 2012 Sep; 26(9):1603-16. PubMed ID: 22798295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]